Navigation Links
Mass. General team develops potentially safer general anesthetic
Date:7/22/2009

A team of Massachusetts General Hospital (MGH) physicians has developed a new general anesthetic that may be safer for critically ill patients. In the August issue of Anesthesiology, they describe preclinical studies of the drug called MOC-etomidate a chemically altered version of an exiting anesthetic which does not cause the sudden drop in blood pressure seen with most anesthetics or prolonged suppression of adrenal gland activity, a problem with the original version of the drug.

"We have shown that making a version of etomidate that is broken down very quickly in the body reduces the duration of adrenal suppression while retaining etomidate's benefit of keeping blood pressure much more stable than other anesthetics do," says Douglas Raines, MD, of the MGH Department of Anesthesia, Critical Care and Pain Medicine, who led the study.

Almost all general anethetic agents reduce blood pressure immediately after they are administered, which is not a problem for young and healthy patients but can have serious consequences for those who are elderly, critically ill or suffering from blood loss. For such patients, etomidate is often used to induce anesthesia, but since adrenal suppression sets in quickly and can last for several hours to days, other agents are used to maintain anesthesia during a procedure, requiring very careful monitoring to avoid dangerous blood pressure drops.

In their search for a safer version of etomidate, the research team mimicked the chemical structure of other "soft analogue" drugs derivatives of parent drugs designed to be rapidly metabolized by adding a molecule that causes the drug to broken down by natural enzymes soon after producing its effects. Experiments in tadpoles and rats showed that the new agent, MOC-etomidate, quickly produced anesthesia from which the animals recovered rapidly after administration ceased. The rat study verified that MOC-etomidate had little effect on blood pressure levels and no effect on adrenal activity, even when administered at twice the dosage required to produce anesthesia.

The researchers note that, since the study only examined the effect of a single dose of MOC-etomidate, their next step will be to study continuous infusion of the drug. Additional data must be gathered from animal studies before testing the agent in human patients is feasible. "If all goes well, we expect that we could give a large dose of MOC-etomidate to induce anesthesia and then run a continuous infusion to maintain anesthesia without reducing blood pressure in even very sick patients," Raines says. "We also anticipate that patients will wake more quickly and with less sedation after surgery and anesthesia."


'/>"/>

Contact: Sue McGreevey
smcgreevey@partners.org
617-724-2764
Massachusetts General Hospital
Source:Eurekalert

Related medicine news :

1. Mass. General-based research center will investigate why immune system fails to control hepatitis C
2. Health Affairs Report On Mass. Mandatory Insurance Law Confirms: Strong Public Option Must Be Included in National Health Reform
3. Yankee Equity Solution ("YES") Launches $50 Million Fund for Mass.-Based Medtech Companies
4. Mass. General Hospital receives Gates Foundation grant to expand HIV controllers study
5. AIDS Action Asks Mass. Public Health Council to Forge a State AIDS Plan to Help Stop HIV/AIDS Here
6. Double-Digit Rate Increases Expected Under Mass. Mandatory Health Law; 5% Cap on Rate Hikes Proposed
7. Mass. Judge Denies Request by Breastfeeding Mother for More Break Time on Medical Licensing Exam
8. LCA Congratulates Nominee For Surgeon General
9. U.S. African Chamber Of Commerce Congratulates U.S. on New Surgeon General, May Improve Health Care for Middle Income Families
10. Pelosi Statement on Appointment of Dr. Regina Benjamin as Surgeon General of the United States
11. Obama Taps Alabama Doctor to Be Surgeon General
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... March 29, 2017 , ... AvePoint , the Microsoft Cloud expert, is ... Richmond, Virginia, located at the Riverfront Plaza, 901 East Byrd Street. AvePoint is celebrating ... Ralph S. Northam and Mayor of Richmond Levar M. Stoney. , Founded in 2001, ...
(Date:3/28/2017)... ... March 28, 2017 , ... Tuesday, March 28, 2017, ... public to take the Diabetes Risk Test to find out if they are at ... World Airports will light up the evening sky by programming the LAX pylons the ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... its award-winning team. Ruel Williamson brings his extensive knowledge of appraisals, property values, ... leader in the real estate valuation industry for more than 40 years. , ...
(Date:3/28/2017)... ... March 29, 2017 , ... ... thyroid pharmacist Dr. Isabella Wentz, Pharm.D., FASCP. The program was recently launched on ... answering common questions regarding thyroid function. , Dr. Izabella Wentz is a ...
(Date:3/28/2017)... ... 28, 2017 , ... Medforce Technologies, Inc., a leading provider ... has joined the National Association for Home Care and Hospice (NAHC), the largest ... dying Americans of all ages and the caregiver who provide them with in-home ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... , March 29, 2017 On March 28, the U.S. ... adult patients with relapsing forms of multiple sclerosis (MS) ... first drug approved by the FDA for PPMS. Ocrevus ... professional.  "Multiple sclerosis can have a ... Dunn , M.D., director of the Division of Neurology ...
(Date:3/29/2017)... March 29, 2017 FinancialBuzz.com News Commentary  ... The U.S. could see ... a new report published by New Frontier Data, the legal cannabis ... pace of cannabis legalization in the United States ... considered to be a major factor that drives growth in this ...
(Date:3/28/2017)... YORK , March 28, 2017 "Chemotherapy Induced Neutropenia ... overview of the disease and global market trends of the Chemotherapy ... States , Europe ( France ... , Spain , UK) and Japan ... (RoE) and rest of the world (RoW). The ...
Breaking Medicine Technology: